Using engineered T cells reduced acute, chronic GVHDFebruary 23, 2021TransplantALLAMLB Cell LymphomaMyelodysplastic SyndromeCellular Therapy
Steroid complications in GVHD common, boost costs of careFebruary 19, 2021TransplantALLMultiple MyelomaDLBCLB Cell Lymphoma
Chronic GVHD therapies offer hope for treating refractory diseaseFebruary 17, 2021TransplantMyelodysplastic SyndromeMultiple MyelomaALLAMLDLBCLB Cell Lymphoma
Allo-HSCT improves disease-free, but not overall survival in adults with ALL, compared with ped-inspired chemoJanuary 20, 2021ALL
In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemoDecember 22, 2020ALL
Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapyDecember 16, 2020ALL
Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomabDecember 11, 2020ALL
COVID-19–related outcomes poor for patients with hematologic disease in ASH registryDecember 5, 2020COVID-19 UpdatesALLMultiple MyelomaB Cell LymphomaNon-Hodgkin Lymphoma
Are HMAS appropriate for posttransplant maintenance in acute leukemias?November 5, 2020ALLTransplantAMLMyelodysplastic Syndrome
Study: Complications from childhood ALL and its treatment are common, but can be managedOctober 15, 2020ALL
Orthopedic problems in children can be the first indication of acute lymphoblastic leukemiaSeptember 30, 2020ALL
